NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy MDGL

*Your capital is at risk

$488.15

+35.29 (+7.79%)

At Close: Jun 03, 2026

Madrigal Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -71.10. In total, the insiders bought 159.04K and sold 51.92K MDGL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-71.10
● Buy	159.04K shares
● Sell	51.92K shares
24% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence May 22, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -71.1. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (24% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 06, 2026 Sell	Common Stock S-Sale	Sibold William John President And CEO	CEO / President	1 663 Value: $718.3K
Mar 06, 2026 Sell	Common Stock S-Sale	Kelley Shannon T General Counsel	Officer	360 Value: $155.5K
Mar 06, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	491 Value: $212.1K
Mar 06, 2026 Sell	Common Stock S-Sale	Huntsman Carole Chief Commercial Officer	Officer	419 Value: $181.0K
Mar 06, 2026 Sell	Common Stock S-Sale	Dier Mardi EVP And CFO	C-Suite Officer	646 Value: $279.0K
Mar 04, 2026 Buy	Stock Option (Right to Buy) A-Award	Dier Mardi EVP And CFO	C-Suite Officer	6 519 Value: $2.83M
Mar 04, 2026 Buy	Common Stock A-Award	Sibold William John President And CEO	CEO / President	14 995 Value: $6.52M
Mar 04, 2026 Buy	Stock Option (Right to Buy) A-Award	Sibold William John President And CEO	CEO / President	18 743 Value: $8.15M
Mar 04, 2026 Buy	Common Stock A-Award	Kelley Shannon T General Counsel	Officer	4 017 Value: $1.75M
Mar 04, 2026 Buy	Stock Option (Right to Buy) A-Award	Soergel David Chief Medical Officer	Officer	5 467 Value: $2.38M
Mar 04, 2026 Buy	Common Stock A-Award	Soergel David Chief Medical Officer	Officer	4 374 Value: $1.90M
Mar 04, 2026 Buy	Common Stock A-Award	Dier Mardi EVP And CFO	C-Suite Officer	5 215 Value: $2.27M
Mar 04, 2026 Buy	Stock Option (Right to Buy) A-Award	Kelley Shannon T General Counsel	Officer	5 022 Value: $2.18M
Mar 04, 2026 Buy	Common Stock A-Award	Huntsman Carole Chief Commercial Officer	Officer	3 989 Value: $1.73M
Mar 04, 2026 Buy	Stock Option (Right to Buy) A-Award	Huntsman Carole Chief Commercial Officer	Officer	4 986 Value: $2.17M
Mar 02, 2026 Sell	Common Stock S-Sale	Dier Mardi EVP And CFO	C-Suite Officer	1 183 Value: $505.4K
Feb 23, 2026 Buy	Common Stock M-Exempt	Levy Richard S Director	Director	2 500 Value: $18.4K
Feb 23, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Levy Richard S Director	Director	2 500 Value: $18.4K
Jan 26, 2026 Sell	Common Stock S-Sale	Huntsman Carole Chief Commercial Officer	Officer	340 Value: $167.4K
Jan 26, 2026 Sell	Common Stock S-Sale	Huntsman Carole Chief Commercial Officer	Officer	570 Value: $281.9K
Jan 26, 2026 Sell	Common Stock S-Sale	Sibold William John President And CEO	CEO / President	1 577 Value: $776.5K
Jan 26, 2026 Sell	Common Stock S-Sale	Taub Rebecca Director	Director	647 Value: $318.6K
Jan 26, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Levy Richard S Director	Director	4 000 Value: $65.8K
Jan 26, 2026 Buy	Common Stock M-Exempt	Levy Richard S Director	Director	4 000 Value: $65.8K
Jan 20, 2026 Sell	Common Stock S-Sale	Kelley Shannon T General Counsel	Officer	263 Value: $129.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,...

Read Full Profile Here